247 related articles for article (PubMed ID: 17542774)
1. A febrile neutropenic patient with Enterococcus gallinarum sepsis treated with daptomycin and gentamicin.
Barber GR; Lauretta J; Saez R
Pharmacotherapy; 2007 Jun; 27(6):927-32. PubMed ID: 17542774
[TBL] [Abstract][Full Text] [Related]
2. Management of gram-positive coccal bacteremia and hemodialysis.
Fitzgibbons LN; Puls DL; Mackay K; Forrest GN
Am J Kidney Dis; 2011 Apr; 57(4):624-40. PubMed ID: 21333430
[TBL] [Abstract][Full Text] [Related]
3. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin.
Cunha BA; Mickail N; Eisenstein L
Heart Lung; 2007; 36(6):456-61. PubMed ID: 18005808
[TBL] [Abstract][Full Text] [Related]
4. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy.
Lewis JS; Owens A; Cadena J; Sabol K; Patterson JE; Jorgensen JH
Antimicrob Agents Chemother; 2005 Apr; 49(4):1664-5. PubMed ID: 15793168
[No Abstract] [Full Text] [Related]
5. Clinical experience with daptomycin: bacteraemia and endocarditis.
Levine DP
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii35-39. PubMed ID: 18829724
[TBL] [Abstract][Full Text] [Related]
6. Daptomycin.
Enoch DA; Bygott JM; Daly ML; Karas JA
J Infect; 2007 Sep; 55(3):205-13. PubMed ID: 17629567
[TBL] [Abstract][Full Text] [Related]
7. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection.
Munoz-Price LS; Lolans K; Quinn JP
Clin Infect Dis; 2005 Aug; 41(4):565-6. PubMed ID: 16028170
[No Abstract] [Full Text] [Related]
8. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.
Kanafani ZA; Corey GR
Expert Rev Anti Infect Ther; 2007 Apr; 5(2):177-84. PubMed ID: 17402833
[TBL] [Abstract][Full Text] [Related]
9. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
[TBL] [Abstract][Full Text] [Related]
10. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
Steenbergen JN; Alder J; Thorne GM; Tally FP
J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
[TBL] [Abstract][Full Text] [Related]
11. Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies.
Steenbergen JN; Mohr JF; Thorne GM
J Antimicrob Chemother; 2009 Dec; 64(6):1130-8. PubMed ID: 19825818
[TBL] [Abstract][Full Text] [Related]
12. Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans.
Green MR; Anasetti C; Sandin RL; Rolfe NE; Greene JN
J Oncol Pharm Pract; 2006 Sep; 12(3):179-81. PubMed ID: 17022872
[TBL] [Abstract][Full Text] [Related]
13. Infective endocarditis caused by daptomycin-resistant Enterococcus faecalis: a case report.
Kanafani ZA; Federspiel JJ; Fowler VG
Scand J Infect Dis; 2007; 39(1):75-7. PubMed ID: 17366018
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).
Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2009 Oct; 65(2):158-62. PubMed ID: 19748426
[TBL] [Abstract][Full Text] [Related]
15. Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers.
Sader HS; Watters AA; Fritsche TR; Jones RN
J Chemother; 2008 Feb; 20(1):28-32. PubMed ID: 18343740
[TBL] [Abstract][Full Text] [Related]
16. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients.
Chaftari AM; Hachem R; Mulanovich V; Chemaly RF; Adachi J; Jacobson K; Jiang Y; Raad I
Int J Antimicrob Agents; 2010 Aug; 36(2):182-6. PubMed ID: 20452752
[TBL] [Abstract][Full Text] [Related]
18. A therapeutic benefit of daptomycin against glycopeptide-resistant gram-positive cocci bloodstream infections under neutropenia.
Matsuda K; Koya J; Toyama K; Ikeda M; Arai S; Nakamura F; Okugawa S; Moriya K; Kurokawa M
J Infect Chemother; 2017 Nov; 23(11):788-790. PubMed ID: 28743428
[TBL] [Abstract][Full Text] [Related]
19. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).
Mohr JF; Friedrich LV; Yankelev S; Lamp KC
Int J Antimicrob Agents; 2009 Jun; 33(6):543-8. PubMed ID: 19201165
[TBL] [Abstract][Full Text] [Related]
20. Optimizing antimicrobial therapy for gram-positive bloodstream infections in patients on hemodialysis.
Pai AB; Pai MP
Adv Chronic Kidney Dis; 2006 Jul; 13(3):259-70. PubMed ID: 16815231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
